These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 348319)

  • 1. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
    Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 3. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
    Sanz Ortíz J; Saiz García F
    Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
    [No Abstract]   [Full Text] [Related]  

  • 5. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
    Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 8. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
    Anderson G; Payne H
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
    Kanda T; Oka M; Hara K; Koteda T; Ishizaki T; Ikebe A; Nakano M; Iwasaki H; Tsutsumi T; Okuno K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):12-8. PubMed ID: 3009666
    [No Abstract]   [Full Text] [Related]  

  • 10. [Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma].
    Kurita Y; Yokoyama A; Kinameri K; Matsuura N; Sano K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):108-11. PubMed ID: 3009665
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
    Wolff SN; Birch R; Sarma P; Greco FA
    Cancer Treat Rep; 1986 May; 70(5):583-7. PubMed ID: 3011257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
    Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
    Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.
    Tempero M; Kessinger A; Lemon HM
    Cancer Clin Trials; 1981; 4(2):155-7. PubMed ID: 6265110
    [No Abstract]   [Full Text] [Related]  

  • 14. Etoposide (VP-16-213). Current status of an active anticancer drug.
    O'Dwyer PJ; Leyland-Jones B; Alonso MT; Marsoni S; Wittes RE
    N Engl J Med; 1985 Mar; 312(11):692-700. PubMed ID: 2983208
    [No Abstract]   [Full Text] [Related]  

  • 15. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide in small cell lung cancer resistant to prior chemotherapy.
    Asbury RF; Rubins J; Bennett JM
    Cancer Treat Rep; 1983 Oct; 67(10):951-2. PubMed ID: 6313187
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose etoposide (VP-16) in small-cell lung cancer.
    Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
    Scagliotti G; Lodico D; Gozzelino F; Pescetti G
    Chemioterapia; 1984 Oct; 3(5):324-6. PubMed ID: 6532545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
    Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
    [No Abstract]   [Full Text] [Related]  

  • 20. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
    Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.